Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 691

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 16K
Chunk 691
---
) attributable to the Company 25,504 25,658 51,162 50,272 ( 654) 100,780
Depreciation/amortization ( 7,640) - ( 7,640) ( 344) ( 223) ( 8,207)
Additions to non-current assets (other than financial instruments and deferred tax assets) 41,338 - 41,338 330 86 41,754

F-51

Table of Contents

Year Ended December 31, 2022
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Oncology/Immunology
Marketed Other
R& D Products Subtotal Ventures Unallocated Total
(in US$ ’ 000)
Revenue from external customers 39,202 124,642 163,844 262,565 - 426,409
Cost of revenue - ( 69,192) ( 69,192) ( 241,911) - ( 311,103)
Research and development expenses ( 386,893) - ( 386,893) - - ( 386,893)
Selling expenses - ( 33,862) ( 33,862) ( 10,071) - ( 43,933)
Administrative expenses ( 55,307) ( 3,087) ( 58,394) ( 3,482) ( 30,297) ( 92,173)
Interest income 678 - 678 272 8,649 9,599
Interest expense - - - - ( 652) ( 652)
Equity in earnings of an equity investee, net of tax 5 - 5 49,748 - 49,753
Income tax (expense)/benefit 5,501 ( 631) 4,870 ( 1,345) ( 3,242) 283
Other segment items ( 5,965) ( 503) ( 6,468) ( 1,172) ( 4,485) ( 12,125)
Net (loss)/income attributable to the Company ( 402,779) 17,367 ( 385,412) 54,604 ( 30,027) ( 360,835)
Depreciation/amortization ( 8,060) - ( 8,060) (